Vericel Q2 Earnings Call Highlights
Vericel (NASDAQ: VCEL) reported Q2 earnings call updates. Burn Care revenue rose 22% to about $12M, with Epicel at $10.4M and NexoBrid above $1.5M. 2026 guidance was raised to $330M-$340M total revenue, MACI to $284M-$290M, Burn Care to $46M-$50M, and Q3 revenue to $76.5M-$78.5M. Board authorized a $200M buyback.
How this was made
The 30-second read
Why it matters
Traders can update models for 2026 revenue and segment mix (MACI and Burn Care) based on the raised guidance, while monitoring execution risks around UK commercialization, BARDA procurement timing, and the pace of margin/EBITDA improvement.
Market read
Guidance raise plus first buyback authorization are actionable catalysts, while margin guidance is unchanged and future profitability improvement is pushed more meaningfully into 2027.
What to watch
UK NICE technology assessment outcome and the timing of BARDA procurement ramp in Q3 could be key swing factors versus the headline guidance.
Background
The piece summarizes Vericel’s Q2 earnings call, covering MACI training and clinical/regulatory plans, Burn Care franchise growth, updated 2026 guidance, and a new $200M repurchase authorization.
Ticker impact
Vericel raised 2026 revenue guidance to $330M-$340M and MACI revenue to $284M-$290M, plus authorized a $200M share repurchase.
Likely positive bias for the stock into the next trading sessions as traders price higher 2026 growth and capital return, offset by unchanged gross margin guidance.
The article discloses specific updated financial targets (total, MACI, Burn Care) and a new $200M repurchase authorization, which typically supports sentiment. However, it does not provide new clinical efficacy results, so upside may be capped until additional data or regulatory milestones land.
Market effects
Reinforces demand momentum in regenerative medicine franchises (MACI) and burn-care products (Epicel, NexoBrid), potentially supporting sentiment toward cell-therapy peers.
UK MACI marketing authorization application and potential 2027 launch could shift expectations for European cartilage-injury treatment adoption.
BARDA procurement activity tied to Burn Care guidance highlights continued US government demand support for advanced wound/burn therapies.
Counterpoint
Raised revenue guidance with maintained gross margin and only 2027 EBITDA expansion suggests near-term profitability may not improve as much as growth, limiting multiple expansion.
Key entities
- companyVericel Corporation
NASDAQ-listed regenerative medicine company; raised 2026 guidance, outlined MACI adoption and UK plans, and authorized a $200M share repurchase.
- productMACI
Autologous cultured chondrocytes therapy for knee cartilage defects; guidance and UK marketing authorization application discussed.
- productNexoBrid
Burn care therapy; revenue growth and ordering-center momentum discussed.
- government programBARDA
US government procurement support referenced for Burn Care, with expected Q3 procurement revenue.
